Abstract
Derived from proopiomelanocortin by proteolytic processing, melanocortins have been implicated in a wide range of physiological processes. Melanocortins exert their physiological effects by binding to specific receptors on the surface of cell membranes. To date, five subtypes of melanocortin receptors (MC1 - MC5) have been identified, all of which are G-protein coupled receptor whose activation leads to increase in intracellular cyclic 3,5-adenosine monophosphate formation. Of these, the MC4 receptor is expressed predominantly throughout the central nervous system, particularly, in areas related to stress responses and emotional states. Expression of the MC4 receptor is regulated by stress exposure. Reports also indicate that stimulation of the MC4 receptor activates the hypothalamus-pituitary-adrenal axis, and that the MC4 receptor mediates stress-related behaviors and anxiety in rodents. Recently developed selective MC4 receptor antagonists have demonstrated antidepressant and anxiolytic effects in several animal models of depression and anxiety. MC4 receptor antagonists are effective, particularly under conditions of high stress, which may be consistent with the etiology of depression and anxiety. This review describes the involvement of the MC4 receptor in stress response and discusses the potential value of MC4 receptor antagonists for the treatment of stress-related disorders such as depression and anxiety.
Keywords: mc4 receptor, melanocortin, antidepressant, anxiolytic, depression, anxiety, hypothalamus-pituitary-adrenal axis
Current Topics in Medicinal Chemistry
Title: Melanocortin-4 Receptor Antagonists for the Treatment of Depression and Anxiety Disorders
Volume: 7 Issue: 11
Author(s): Taketoshi Okubo and Shigeyuki Chaki
Affiliation:
Keywords: mc4 receptor, melanocortin, antidepressant, anxiolytic, depression, anxiety, hypothalamus-pituitary-adrenal axis
Abstract: Derived from proopiomelanocortin by proteolytic processing, melanocortins have been implicated in a wide range of physiological processes. Melanocortins exert their physiological effects by binding to specific receptors on the surface of cell membranes. To date, five subtypes of melanocortin receptors (MC1 - MC5) have been identified, all of which are G-protein coupled receptor whose activation leads to increase in intracellular cyclic 3,5-adenosine monophosphate formation. Of these, the MC4 receptor is expressed predominantly throughout the central nervous system, particularly, in areas related to stress responses and emotional states. Expression of the MC4 receptor is regulated by stress exposure. Reports also indicate that stimulation of the MC4 receptor activates the hypothalamus-pituitary-adrenal axis, and that the MC4 receptor mediates stress-related behaviors and anxiety in rodents. Recently developed selective MC4 receptor antagonists have demonstrated antidepressant and anxiolytic effects in several animal models of depression and anxiety. MC4 receptor antagonists are effective, particularly under conditions of high stress, which may be consistent with the etiology of depression and anxiety. This review describes the involvement of the MC4 receptor in stress response and discusses the potential value of MC4 receptor antagonists for the treatment of stress-related disorders such as depression and anxiety.
Export Options
About this article
Cite this article as:
Taketoshi Okubo and Shigeyuki Chaki , Melanocortin-4 Receptor Antagonists for the Treatment of Depression and Anxiety Disorders, Current Topics in Medicinal Chemistry 2007; 7 (11) . https://dx.doi.org/10.2174/156802607780906618
DOI https://dx.doi.org/10.2174/156802607780906618 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Energetic Metabolic Roles in Pulmonary Arterial Hypertension and Right Ventricular Remodeling
Current Pharmaceutical Design Endothelial Remodelling and Intracellular Calcium Machinery
Current Molecular Medicine The Metabolic Approach in Patients with Heart Failure: Effects on Left Ventricle Remodeling
Current Pharmaceutical Design Endothelin Receptor Antagonists: A New Therapeutic Option for Improving the Outcome after Solid Organ Transplantation?
Current Vascular Pharmacology Insulin Resistance and Hypertension
Current Hypertension Reviews The Effect of Statin Therapy on Arterial Stiffness by Measuring Pulse Wave Velocity: A Systematic Review
Current Vascular Pharmacology Heart Failure in South America
Current Cardiology Reviews Angiotensin II and Abdominal Aortic Aneurysms: An update
Current Pharmaceutical Design Ongoing In Vivo Studies with Cytoskeletal Drugs in Tau Transgenic Mice
Current Alzheimer Research Current Concepts in the Management of Diabetic Polyneuropathy
Current Diabetes Reviews Cardiac Innervation and Sudden Cardiac Death
Current Cardiology Reviews Pathogenetic Pathways of Cardiorenal Syndrome and their Possible Therapeutic Implications
Current Pharmaceutical Design Vascular Endothelial Growth Factor in Central Nervous System Injuries – A Vascular Growth Factor Getting Nervous?
Current Neurovascular Research Angiotensin (1-7) and other Angiotensin Peptides
Current Pharmaceutical Design Isoprostanes as Biomarkers and Mediators of Oxidative Injury in Infant and Adult Central Nervous System Diseases
Current Neurovascular Research Hypereosinophilic Syndrome, Churg-Strauss Syndrome and Parasitic Diseases: Possible Links between Eosinophilia and Thrombosis
Current Vascular Pharmacology Congestive Heart Failure and Thyroid Dysfunction: The Role of the Low T3 Syndrome and Therapeutic Aspects
Endocrine, Metabolic & Immune Disorders - Drug Targets How Should We Treat Hypertension and Dyslipidemia in Patients with Prediabetes?
Current Pharmaceutical Design Drug Therapy Aimed at Adenylyl Cyclase to Regulate Cyclic Nucleotide Signaling
Endocrine, Metabolic & Immune Disorders - Drug Targets New Challenges for ACE-Inhibitors in Vascular Diseases
Drug Design Reviews - Online (Discontinued)